Patent US4215111A successfully refreshed from Google Patents.
US4215111A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptides having ubiquitin-like activity
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1979-03-14
•
Granted: 1980-07-29
•
Expires: 1999-03-14
Abstract
Abstract Peptides of the following formula: A-B wherein A is a member selected from the group consisting of deamino-GLN, GLN, and (SAR)n-GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH2, decarboxy-LYS, <IMAGE> LYS-SAR-OH and LYS-SAR-NH2, have significantly increased ubiquitin-like activity. Also provided are therapeutic compositions and methods for use thereof.
Inventors
- 👤 Gideon Goldstein
- 👤 George Heavner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 21:03
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; A; A61; A61P; A61P37/00; C07K14/00; C07K14/435; C07K14/575; C07K14/66; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06017; C07K5/06026; C07K5/06104; C07K5/08; C07K5/0802; C07K5/0804; C07K5/0806; C07K5/10; C07K5/1002; C07K5/1005; C07K5/1008; A61K; A61K38/00
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
75 words
A peptide possessing ubiquitin-like activity having the formula: A-B wherein A is a member selected from the group consisting of deamino GLN, GLN, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR17## LYS-SAR-OH and LYS-SAR-NH 2 , provided that when A is GLN, B is other than LYS-OH, and the pharmaceutically-acceptable acid addition salts thereof.
Claim 2
Dependent Claim
75 words
A peptide possessing ubiquitin-like activity having the formula: A-B wherein A is a member selected from the group consisting of deamino GLN, GLN, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR17## LYS-SAR-OH and LYS-SAR-NH 2 , provided that when A is GLN, B is other than LYS-OH, and the pharmaceutically-acceptable acid addition salts thereof.
Claim 3
Dependent Claim
43 words
The peptide of claim 1 wherein A is a member selected from the group consisting of deamino-GLN, and H-(SAR) n -GLN; n is 2, 3, or 4; and B is a member selected from the group consisting of LYS-OH and LYS-NH 2 .
Claim 4
Dependent Claim
24 words
The peptide of claim 1 of formula (deamino-GLN)-LYS-C, where C is a member selected from the group consisting of OH and NH 2 .
Claim 5
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 6
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 7
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 8
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 9
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 10
Dependent Claim
11 words
A peptide of formula H-SAR-SAR-SAR-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 11
Dependent Claim
11 words
A peptide of formula H-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 12
Dependent Claim
11 words
A peptide of formula H-SAR-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 13
Dependent Claim
11 words
A peptide of formula H-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 14
Dependent Claim
11 words
A peptide of formula H-GLN-LYS-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 15
Dependent Claim
10 words
A peptide of formula deamino-GLN-LYS-OH and the pharmaceutically-acceptable salts thereof.
Claim 16
Dependent Claim
10 words
A peptide of formula deamino-GLN-LYS-OH and the pharmaceutically-acceptable salts thereof.
Claim 17
Dependent Claim
20 words
A therapeutic composition of matter comprising a therapeutically effective amount of the peptide of claim 1 in a pharmaceutically-acceptable carrier.
Claim 18
Dependent Claim
86 words
A therapeutic composition of matter for parenteral administration comprising in a pharmaceutically acceptable carrier from about 10 pg/kg to about 100 ng/kg body weight of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR18## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 19
Dependent Claim
86 words
A therapeutic composition of matter for parenteral administration comprising in a pharmaceutically acceptable carrier from about 10 pg/kg to about 100 ng/kg body weight of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR18## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 20
Dependent Claim
86 words
A therapeutic composition of matter for oral administration comprising in a pharmaceutically acceptable carrier from about 1 ng/kg to about 100 μg/kg body weight of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR19## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 21
Dependent Claim
86 words
A therapeutic composition of matter for oral administration comprising in a pharmaceutically acceptable carrier from about 1 ng/kg to about 100 μg/kg body weight of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR19## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 22
Independent Claim
85 words
A method for the treatment of conditions resulting from relative or absolute T cell deficiencies which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -(GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR20## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 23
Independent Claim
85 words
A method for the treatment of conditions resulting from relative or absolute T cell deficiencies which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -(GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR20## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 24
Independent Claim
85 words
A method for the treatment of conditions resulting from relative or absolute B cell deficiencies which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR21## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 25
Independent Claim
85 words
A method for the treatment of conditions resulting from relative or absolute B cell deficiencies which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR21## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 26
Independent Claim
84 words
A method for inducing bone marrow cells to develop the characteristics of thymus-derived lymphocytes which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxyl-LYS ##STR22## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptble acid addition salt thereof.
Claim 27
Independent Claim
84 words
A method for inducing bone marrow cells to develop the characteristics of thymus-derived lymphocytes which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxyl-LYS ##STR22## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptble acid addition salt thereof.
Claim 28
Independent Claim
85 words
A method for inducing bone marrow cells to develop the characteristics of immunocompetent B cells which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR23## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 29
Independent Claim
85 words
A method for inducing bone marrow cells to develop the characteristics of immunocompetent B cells which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR23## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 30
Independent Claim
93 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficiencies of the thymus which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR24## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 31
Independent Claim
93 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficiencies of the thymus which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR24## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 32
Independent Claim
98 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficienices of the body tissues which differentiate B cells which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR25## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 33
Independent Claim
98 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficienices of the body tissues which differentiate B cells which comprises administration of a therapeutically effective amount of a peptide having the formula A-B wherein A is a member selected from the group consisting of deamino GLN, GLY, and (SAR) n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH 2 , decarboxy-LYS, ##STR25## LYS-SAR-OH and LYS-SAR-NH 2 , or a pharmaceutically-acceptable acid addition salt thereof.
Claim 34
Dependent Claim
11 words
A peptide of formula H-GLN-LYS-SAR-NH 2 and the pharmaceutically-acceptable salts thereof.
Claim 35
Dependent Claim
11 words
A peptide of formula H-GLN-LYS-SAR-NH 2 and the pharmaceutically-acceptable salts thereof.
References Cited (Backward Citations)
US4113858A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-07-29 | 1984-01-28 | 1984-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-07-29 | 1988-01-28 | 1988-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-07-29 | 1992-01-28 | 1992-07-29 | $7700.00 | Window Closed / Lapsed |